Literature DB >> 22067669

The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Jose Luis Olmos-Serrano1, Joshua G Corbin, Mark P Burns.   

Abstract

Hyperactivity, hypersensitivity to auditory stimuli, and exaggerated fear are common behavioral abnormalities observed in individuals with fragile X syndrome (FXS), a neurodevelopmental disorder that is the most common genetic cause of autism. Evidence from studies of the Fmr1 knockout (KO) mouse model of FXS supports the notion that impaired GABAergic transmission in different brain regions such as the amygdala, striatum or cerebral cortex is central to FXS behavioral abnormalities. This suggests that the GABAergic system might be an intriguing target to ameliorate some of the phenotypes in FXS. Our recent work revealed that THIP (gaboxadol), a GABA(A) receptor agonist, can restore principal neuron excitability deficits in the Fmr1 KO amygdala, suggesting that THIP may also restore some of the key behavioral abnormalities in Fmr1 KO mice. Here, we reveal that THIP significantly attenuated hyperactivity in Fmr1 KO mice, and reduced prepulse inhibition in a volume-dependent manner. In contrast, THIP did not reverse the deficits in cued fear or startle response. Thus, this study shows that enhancing GABAergic transmission can correct specific behavioral phenotypes of the Fmr1 KO mouse further supporting that targeting the GABAergic system, and specifically tonic inhibition, might be important for correcting or ameliorating some key behaviors in FXS.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067669      PMCID: PMC3254038          DOI: 10.1159/000332884

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  57 in total

1.  A functional role for dopamine transmission in the amygdala during conditioned fear.

Authors:  F A Guarraci; R J Frohardt; S L Young; B S Kapp
Journal:  Ann N Y Acad Sci       Date:  1999-06-29       Impact factor: 5.691

2.  Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety.

Authors:  Jamie L Maguire; Brandon M Stell; Mahsan Rafizadeh; Istvan Mody
Journal:  Nat Neurosci       Date:  2005-05-15       Impact factor: 24.884

3.  Prevalence of fragile X syndrome.

Authors:  G Turner; T Webb; S Wake; H Robinson
Journal:  Am J Med Genet       Date:  1996-07-12

4.  Evidence that GABA transmission mediates context-specific extinction of learned fear.

Authors:  J A Harris; R F Westbrook
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

5.  Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report.

Authors:  L J Miller; D N McIntosh; J McGrath; V Shyu; M Lampe; A K Taylor; F Tassone; K Neitzel; T Stackhouse; R J Hagerman
Journal:  Am J Med Genet       Date:  1999-04-02

6.  Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome.

Authors:  Ming-Gao Zhao; Hiroki Toyoda; Shanelle W Ko; Hoi-Ki Ding; Long-Jun Wu; Min Zhuo
Journal:  J Neurosci       Date:  2005-08-10       Impact factor: 6.167

7.  Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.

Authors:  Sean M J McBride; Catherine H Choi; Yan Wang; David Liebelt; Evan Braunstein; David Ferreiro; Amita Sehgal; Kathleen K Siwicki; Thomas C Dockendorff; Hanh T Nguyen; Thomas V McDonald; Thomas A Jongens
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

8.  Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.

Authors:  Abdeslem El Idrissi; Xiao-Hua Ding; Jason Scalia; Ekkhart Trenkner; W Ted Brown; Carl Dobkin
Journal:  Neurosci Lett       Date:  2004-12-23       Impact factor: 3.046

Review 9.  Annotation: Deconstructing the attention deficit in fragile X syndrome: a developmental neuropsychological approach.

Authors:  K M Cornish; J Turk; J Wilding; V Sudhalter; F Munir; F Kooy; R Hagerman
Journal:  J Child Psychol Psychiatry       Date:  2004-09       Impact factor: 8.982

10.  A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse.

Authors:  Q J Yan; P K Asafo-Adjei; H M Arnold; R E Brown; R P Bauchwitz
Journal:  Genes Brain Behav       Date:  2004-12       Impact factor: 3.449

View more
  60 in total

1.  The effect of injury severity on behavior: a phenotypic study of cognitive and emotional deficits after mild, moderate, and severe controlled cortical impact injury in mice.

Authors:  Patricia M Washington; Patrick A Forcelli; Tiffany Wilkins; David N Zapple; Maia Parsadanian; Mark P Burns
Journal:  J Neurotrauma       Date:  2012-08-03       Impact factor: 5.269

Review 2.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome.

Authors:  Neal R Swerdlow
Journal:  Neurosci Biobehav Rev       Date:  2012-09-24       Impact factor: 8.989

4.  Altered nocifensive behavior in animal models of autism spectrum disorder: The role of the nicotinic cholinergic system.

Authors:  Li Wang; Luis E F Almeida; Margaret Nettleton; Alfia Khaibullina; Sarah Albani; Sayuri Kamimura; Mehdi Nouraie; Zenaide M N Quezado
Journal:  Neuropharmacology       Date:  2016-09-13       Impact factor: 5.250

5.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Authors:  Craig A Erickson; Logan K Wink; Balmiki Ray; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Debomoy K Lahiri; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

6.  A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA(A) receptors.

Authors:  M L Jensen; K A Wafford; A R Brown; D Belelli; J J Lambert; N R Mirza
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 7.  Altered Neuronal and Circuit Excitability in Fragile X Syndrome.

Authors:  Anis Contractor; Vitaly A Klyachko; Carlos Portera-Cailliau
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

Review 8.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

9.  Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Authors:  Maria Isabel Carreno-Munoz; Fabienne Martins; Maria Carmen Medrano; Elisabetta Aloisi; Susanna Pietropaolo; Corentin Dechaud; Enejda Subashi; Guillaume Bony; Melanie Ginger; Abdelmalik Moujahid; Andreas Frick; Xavier Leinekugel
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

Review 10.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.